Mindbytes Jul 16, 2026
InnoCare Advances Vitiligo Drug After Phase 2 Result
InnoCare's TYK2 inhibitor soficitinib hits vitiligo Phase 2 endpoint, advancing to Phase 3. Competitive autoimmune skin disorder trial shows strong F-VASI improvement.
Linsey 1 min read